tyb
Castle Biosciences, Inc sold by Sofinnova Healthquest Ptnrs: $8.62m-May 12
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Number of employees : 133 people.
https://www.marketscreener.com/CASTLE-BIOSCIENCES-INC-62745768/company/
This sale is filed under David Kabakoff- Executive Partner, Private Equity
David Kabakoff joined Sofinnova as Executive Partner in 2007. He represents Sofinnova as the Chairman of NextCure, and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, Rainier Therapeutics and Neurana. He also serves as Chairman of Lineagen and as a Director of bioTheranostics and Castle Biosciences. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune, and as a Director of InterMune and Principia.
Prior to Sofinnova, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer until its acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura, a specialty pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development. Earlier, David was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech.
https://www.sofinnova.com/team/david-kabakoff/
https://www.finviz.com/insidertrading.ashx?oc=1579382&tc=7
highly unlikely however that is probably where the "they won't be able to walk the streets" will come in
VVLL876 and VVLL821 P-8 shift change off Space Coast from NAS Jax
ZAGS65 KC-135R tanker from Fairchild AFB, Spokane heading back down to off-shore SD/TJ border-where it was yesterday with many others.
anime is faggit
Fed Buys $305 Million of ETFs at Start of Historic Program
The Federal Reserve bought $305 million of exchange-traded funds in the first two days of its historic intervention into U.S. corporate debt markets, according to data published Thursday.
The figures were revealed in the central bank’s weekly balance sheet update, which also showed that total assets rose to a new record of $6.93 trillion in the week through May 13. The ETF purchases are part of the latest emergency lending program the Fed has rolled out to help cushion the impact of the coronavirus pandemic on the U.S. economy and financial markets. First announced on March 23, the so-called Secondary Market Corporate Credit Facility has been credited by investors and policy makers alike with having a major calming influence on markets, even well before it officially launched on Tuesday. Under the program, the Fed plans to make both outright purchases of corporate bonds as well as ETFs invested in the asset class, including potentially some sub-investment grade debt.
While the weekly balance sheet data did not disclose which ETFs the Fed bought, the central bank has said it will disclose the names of borrowers participating in the program at least once a month.
https://news.bloomberglaw.com/banking-law/fed-buys-305-million-of-etfs-at-start-of-historic-program